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Intravenously administered mesenchymal stem/stromal cells (MSCs)
engraft only transiently in recipients, but confer long-term thera-
peutic benefits in patients with immune disorders. This suggests
that MSCs induce immune tolerance by long-lasting effects on the
recipient immune regulatory system. Here, we demonstrate that
i.v. infusion of MSCs preconditioned lung monocytes/macrophages
toward an immune regulatory phenotype in a TNF-α–stimulated
gene/protein (TSG)-6–dependent manner. As a result, mice were pro-
tected against subsequent immune challenge in two models of allo-
and autoimmune ocular inflammation: corneal allotransplantation
and experimental autoimmune uveitis (EAU). The monocytes/macro-
phages primed by MSCs expressed high levels of MHC class II, B220,
CD11b, and IL-10, and exhibited T-cell–suppressive activities inde-
pendently of FoxP3+ regulatory T cells. Adoptive transfer of MSC-
induced B220+CD11b+ monocytes/macrophages prevented corneal
allograft rejection and EAU. Deletion of monocytes/macrophages
abrogated the MSC-induced tolerance. However, MSCs with TSG-6
knockdown did not induce MHC II+B220+CD11b+ cells, and failed to
attenuate EAU. Therefore, the results demonstrate a mechanism of
the MSC-mediated immune modulation through induction of innate
immune tolerance that involves monocytes/macrophages.
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Intravenous administration of mesenchymal stem/stromal cells(MSCs) has emerged as a promising cell-based immunotherapy
for autoimmune diseases, graft-vs.-host disease, and transplantation
(1–3). A significant body of data from preclinical and clinical studies
has demonstrated remarkable immunosuppressive capacities
of MSCs in various diseases, but the mechanisms are still difficult
to explain.
One key observation is that therapeutic benefits of MSC ad-
ministration in animal models are achieved without significant
engraftment of the cells; after i.v. infusion, most MSCs reside
transiently within the lung and disappear rapidly with a t1/2 of ap-
proximately 24 h in mice (4, 5). Therefore, direct suppressive ef-
fects of MSCs on the immune system are short-lived, and do not
explain the long-term therapeutic effects observed with MSCs in
clinical and animal studies. In this context, it has been suggested that
MSCs trigger a state of immune tolerance, for example, through the
induction of regulatory T cells (Tregs) (6, 7).
Classically, lymphoid cells such as Tregs have been known to
play a major role in regulating immune responses and maintaining
immune tolerance. Recently, however, myeloid cells, including
monocytes/macrophages, have gained attention as important
mediators of immune regulation and tolerance (8, 9). In line
with this, a few studies demonstrated that MSCs induce the expan-
sion of myeloid cells with immunosuppressive activity and modulate
monocytes/macrophages to an antiinflammatory phenotype, thereby
inhibiting excessive inflammatory responses (10–12).
However, it is not clear whether the MSC-educated myeloid
cells can induce significant immune tolerance to repress adaptive
immune responses in a setting of allo- or autoimmunity. More-
over, little is known about the mechanism(s) whereby MSCs
induce immune tolerance through myeloid cells.
In this study, we demonstrate that i.v. injection of MSCs into
naive mice before immune challenge induces a significant im-
mune tolerance in TNF-α–stimulated gene/protein (TSG)-6–
dependent manner, and prevents the development of immune
responses in two models of allo- and autoimmune ocular in-
flammation: corneal allotransplantation and experimental auto-
immune uveitis (EAU). The MSC-induced tolerance involves a
distinct subset of suppressive monocytes/macrophages in the
lung, and is transferable independently of FoxP3+ Tregs. These
data suggest a mechanism of MSCs in regulating adaptive im-
munity through induction of nonspecific innate tolerance.
Results
MSC Pretreatment Improves Corneal Allograft Survival. We first
tested whether i.v. infusion of MSCs would induce tolerance to
prevent alloimmunity. To this end, we injected 1 × 106 human
bone marrow-derived MSCs (hMSCs) into tail vein of BALB/c
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(H-2d) mice at days −7 and −3, and performed corneal allo-
transplantation at day 0 using C57BL/6 mice (H-2b) as donors
(Fig. 1A). We elected to inject hMSCs 7 and 3 d before
transplantation because previous studies indicate that tolerance
induced by cyclosporine or endotoxin can be sustained for 3–7 d (13,
14). For positive controls, vehicle (HBSS) or 1 × 106 human skin
fibroblasts (Fibro) were injected in place of hMSCs. For negative
controls, syngeneic corneal autografts were performed in BALB/c
mice using BALB/c mice as donors. As a result, the survival of
corneal allografts was significantly prolonged in the hMSC-pre-
treated mice compared with the HBSS- or Fibro-pretreated mice
(Fig. 1 B and C). Histological examination of corneal allografts at
day 28 demonstrated marked corneal stromal swelling with CD3+
cell infiltration in the HBSS-pretreated group, indicating corneal
allograft rejection (Fig. 1D). In contrast, corneal thickness was
normal with well-preserved corneal endothelium and few CD3+
infiltrates in the hMSC-pretreated group, similar to syngeneic
autografts. Molecular assay showed that the levels of IFN-γ and
IL-2 were markedly increased in the corneas of HBSS- or Fibro-
pretreated mice, but significantly reduced in those of hMSC-
pretreated mice (Fig. 1E). Similarly, flow cytometric analysis of
draining cervical lymph nodes (DLNs) revealed that the number
of IFN-γ+CD4+ cells was significantly lower in hMSC-pretreated
mice than in HBSS- or Fibro-pretreated mice (Fig. 1 F and G and
Fig. S1). Together, results indicate that i.v. injection of hMSCs
before corneal transplantation suppressed the immune rejection
and prolonged the corneal allograft survival.
To examine the possibility that hMSCs directly suppress the
immune rejection, we evaluated whether hMSCs were present in
the lung, DLNs, or cornea at day 0 (at the time of corneal trans-
plantation) after i.v. injections of the cells at days −7 and −3. We
carried out quantitative RT-PCR assays at day 0 for human-specific
GAPDH as previously described (4, 5), and detected less than
10 hMSCs in the tissues, an observation consistent with previous
studies (4, 5). Therefore, the beneficial effects of hMSC pre-
treatment in corneal allografts were not attributed to direct
immunosuppression by hMSCs, and suggest induction of immune
tolerance by hMSCs.
MSC Pretreatment Prevents EAU Development. In parallel, we tested
whether hMSC pretreatment would be effective in preventing au-
toimmunity. For this purpose, we used a mouse model of EAU, a
well-established model for human autoimmune intraocular in-
flammation (15). We injected 1 × 106 hMSCs, 1 × 106 Fibro, or the
vehicle (HBSS) into the tail vein of C57BL/6 mice at days −7 and
−3 before EAU induction. At day 0, the mice were immunized by
s.c. injection of the retina-specific antigen interphotoreceptor
retinal binding protein (IRBP) into footpads (Fig. 2A). The retinal
cross-sections at day 21 showed severe disruption of retinal pho-
toreceptor layer in mice pretreated with HBSS or Fibro (Fig. 2B).
In contrast, there was little structural damage with few inflam-
matory infiltrates in the retina of hMSC-pretreated mice, similar
to normal retina without EAU. The disease score assigned by
retinal pathologic examination was significantly lower in hMSC-
treated mice compared with HBSS- or Fibro-treated mice (Fig.
2C). The transcript levels of proinflammatory cytokines, IFN-γ,
IL-2, IL-1β, IL-6, and TNF-α in the whole eyeball were dramati-
cally decreased in the hMSC-pretreated group compared with the
HBSS- or Fibro-pretreated group (Fig. 2D). In addition, flow
cytometric assays of DLNs revealed a significant reduction in the
number of IFN-γ+CD4+ and IL-17+CD4+ cells in hMSC-pre-
treated vs. HBSS-pretreated mice (Fig. 2 E and F and Fig. S1).
Fig. 1. MSC pretreatment prolongs corneal allograft survival. (A) Schema of
MSC pretreatment in a model of corneal allotransplantation. (B) Representa-
tive photographs of the cornea at day 28. (C) Survival curve of corneal grafts.
Allo, allogeneic grafts; Auto, syngeneic autografts. (D) H&E staining and CD3
immunostaining of corneal grafts (original magnification of 100×). (E) Real-
time RT-PCR assays of the cornea. Data indicate the mRNA levels as the relative
ratio to the levels in normal corneas. (F and G) Representative and quantitative
flow cytometry results for IFN-γ and CD4 expression in cells from DLNs. Data
depict the percentage of IFN-γ+CD4+ cells among the total lymph node cells.
Each dot represents an individual animal, and results are presented as mean ±
SD from three independent experiments, each experiment with three mice per
group (*P < 0.05, **P < 0.01, and ***P < 0.001; ns, not significant).
Fig. 2. MSC pretreatment suppresses EAU development. (A) Schema of MSC
pretreatment in a model of EAU. (B) H&E staining of retinal cross-sections. A
marked disruption of the photoreceptor layer was observed in the retinas in
HBSS- and Fibro-treated mice indicating EAU induction (original magnification
of 100×). (C) Disease score assigned by retinal histology. (D) Real-time RT-PCR
assays of the whole eye. Shown are relative values of mRNA levels to the levels
in normal eyes. (E and F) Representative and quantitative flow cytometry results
for CD4, IFN-γ, and IL-17 in DLNs. Data depict the percentage of IFN-γ+CD4+ cells
and IL-17+CD4+ cells among the total lymph node cells. Each dot represents an
individual animal. Results are presented as mean ± SD from three independent
experiments, each experiment with three mice per group (*P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001; ns, not significant).





















Therefore, the results suggest that hMSC pretreatment prevented
EAU development.
We also examined whether the beneficial effects of hMSCs in
corneal allograft rejection and EAUmight be a result of nonspecific
effects of apoptotic cells. However, i.v. injections of hMSCs that
were made apoptotic by repeated cycles of freezing and thawing
(16) did not have any effects on corneal graft survival and EAU
development (Fig. S2).
Collectively, the data demonstrate that i.v. injections of hMSCs
into naive mice induce a state of immune tolerance, and thereby
protect the eye against allo- and autoimmune inflammation.
A Distinct Population of Myeloid Cells Appears in the Lung After MSC
Infusion. Next, we sought to identify the immune cell population
(s) responsible for the hMSC-induced tolerance observed. We
collected the lung, peripheral blood, spleen, and DLNs from the
mice at day 0 after i.v. injection of hMSCs, Fibro, or HBSS into naive
mice at days −7 and −3 (Fig. 3A). The cells from each tissue were
analyzed by flow cytometry for the expression of myeloid lineage
markers (MHC class II, CD11b, CD11c, F4/80, Ly6C, B220), lym-
phoid lineage markers (CD4, CD8, CD19, CD25, FoxP3), and im-
mune regulatory cytokine IL-10. First, we evaluated live cells
for MHC class II expression, and found that the percentage of
MHC class II+ cells was markedly higher in the lung of hMSC-
pretreated mice compared with HBSS-pretreated mice (46.3 ±
4.8% vs. 29.5 ± 6.4%; P = 0.001). Next, we analyzed MHC class
II+ cells, and found that there was a significant difference in
MHC class II+ cell populations based on differential expression
of B220 and CD11b between hMSC- and HBSS-pretreated groups
(Fig. 3B). Quantitative analysis revealed a higher percentage of
MHC class II+B220+CD11b+ cells and a lower percentage of
MHC class II+B220−CD11b+ cells in the lung of hMSC-pretreated
mice compared with HBSS- or Fibro-pretreated mice (Fig. 3C).
Similarly, a significant increase was observed in MHC class II+
B220+CD11b+ cells in peripheral blood, spleen, and DLNs of
hMSC-pretreated mice (Fig. 3 B and C). Further examination of
phenotypic markers revealed that MHC class II+B220+CD11b+
cells expressed high levels of IL-10, F4/80, and Ly6C and a
moderate level of CD11c (Fig. 3D). The cells were negative for
classical lineage markers of T cells (CD4 and CD8) and B cells
(CD19). A number of studies reported that MSCs up-regulate
FoxP3+ Tregs (6, 7). Likewise, we observed a significant increase
in the number of CD4+CD25+FoxP3+ cells in the lung, peripheral
blood, and DLNs in mice pretreated with hMSCs (Fig. S3).
However, the number of CD4+CD25+FoxP3+ cells was markedly
reduced in the spleen of hMSC-pretreated mice.
Next, to determine the kinetics of IL-10, MHC class
II+B220+CD11b+ cells, and CD4+CD25+FoxP3+ cells, we analyzed
the lung, peripheral blood, and DLNs at days 0, 1, 4, and 7 after i.v.
injection of hMSCs into naive mice at days −7 and −3. Time course
showed that the plasma level of IL-10 remained significantly ele-
vated until day 4 (i.e., 7 d after hMSC injection; Fig. 3E). Consistent
with the change in IL-10 levels, the percentage of MHC class
II+B220+CD11b+ cells was significantly increased in the lung,
peripheral blood, and DLNs until day 4, indicating that the cells
persist in mice until at least 7 d after hMSC injection (Fig. 3F).
On the contrary, CD4+CD25+FoxP3+ cells were elevated in the
lung, blood, and DLNs until day 1 (i.e., 4 d after hMSC injection)
in hMSC-pretreated mice, but not different from controls at day
4 and thereafter (Fig. S3).
Together, the results demonstrate that a distinct population of
MHC class II+B220+CD11b+ cells is induced in the lung by i.v.
hMSCs and circulates for at least 7 d postinjection.
MSC-Primed Lung Monocytes/Macrophages Are T-Cell Suppressive. From
the aforementioned observations, we hypothesized that the subset
of lung myeloid cells defined as MHC class II+B220+CD11b+ cells
might be involved in the hMSC-induced tolerance. To better
characterize the cells, we sorted B220+CD11b+ and B220−CD11b+
cells from the lung of mice at day 0 after treatment with i.v. hMSCs
at days −7 and −3. Giemsa staining showed that B220+CD11b+
cells were a morphologically homogenous population of monocytes/
macrophages, and B220−CD11b+ cells were a heterogeneous mix-
ture of monocytes and granulocytes (Fig. 4A). To investigate the
effects of B220+CD11b+ cells on T cells, we cocultured B220+
CD11b+ cells that were isolated from the lung of hMSC-pretreated
mice with CD4+ cells that were purified from blood of naive mice.
To assay T-cell proliferation, CD4+ cells were labeled with car-
boxyfluorescein diacetate succinimidyl ester (CFSE) and stimulated
with anti-CD3/anti-CD28 monoclonal antibodies. Flow cytometric
Fig. 3. Adistinct populationofMHC class II+B220+CD11b+
cells is induced by MSC pretreatment. (A) Schema of
assays. At days −7 and −3, MSC, Fibro, or HBSS vehicle
(BSS) were injected into naive BALB/c mice. At day 0, the
lung, peripheral blood, spleen, and DLNs were collected
for assays. (B and C) Representative and quantitative
flow cytometry results for expression of CD11b and
B220 after gating on MHC class II+ cells. Each dot
represents an individual animal. (D) Representative
flow cytometry plots of phenotypic markers on MHC
class II+B220+CD11b+ subset in the lung of MSC-pre-
treated mice. (E) Time course of plasma IL-10 levels in
mice pretreated with MSC or HBSS. (F) Kinetics of MHC
class II+B220+CD11b+ cells in tissues. Data (mean ± SD)
are representative of at least four independent exper-
iments (each with three mice per group) in MSC and
HBSS groups and three independent experiments (each
with three mice) in Fibro group (*P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001; ns, not significant).
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analysis of CFSE dilution revealed that CD4+ cell proliferation was
significantly repressed by coculture with B220+CD11b+ cells com-
pared with coculture with B220−CD11b+ cells or without coculture
(Fig. 4B). To assay T-cell differentiation, the anti-CD3/anti-CD28–
activated CD4+ cells were primed with Th1- or Th17-polarizing
conditions and cocultured with B220+CD11b+ or B220−CD11b+
cells. The percentage of IFN-γ+CD4+ and IL-17+CD4+ cells was
significantly lower in CD4+ cells cocultured with B220+CD11b+
cells than in those cocultured with B220−CD11b+ cells or without
coculture (Fig. 4C). However, B220+CD11b+ or B220−CD11b+
cells did not promote the expansion of CD4+CD25+FoxP3+ cells
(Fig. S4). Therefore, the data indicate that B220+CD11b+ mono-
cytes/macrophages from the hMSC-primed lung inhibit T-cell pro-
liferation and Th1/Th17 differentiation.
MSC-Primed Lung Monocytes/Macrophages Induce Tolerance.To confirm
the role of the hMSC-induced B220+CD11b+ monocytes/macro-
phages in vivo, we transferred B220+CD11b+ or B220−CD11b+
cells isolated as described earlier into naive BALB/c or C57BL/6
mice through a tail vein. Corneal allotransplantation was then
performed in BALB/c mice or EAU was induced in C57BL/6 mice
(Fig. 5). The infusion of B220+CD11b+ cells significantly pro-
longed the survival of corneal allografts, whereas B220−CD11b+
cells did not (Fig. 5 A and B). The percentage of IFN-γ+CD4+
cells in DLNs was significantly reduced in the mice receiving
B220+CD11b+ cells (Fig. 5C). Similarly, the expression of IFN-γ
and IL-2 in the cornea was markedly decreased in the mice treated
with B220+CD11b+ cells (Fig. 5D). To further determine whether
monocytes/macrophages are necessary for the MSC-induced tol-
erance, we depleted mice of monocytes/macrophages by i.v. ad-
ministration of clodronate-encapsulated liposome at days −8 and
−4 and treated them with hMSCs at days −7 and −3. As the
maximum monocyte/macrophage depletion occurs 24 h after
clodronate liposome delivery (17), the mice were depleted of
monocytes/macrophages at the time of hMSC injection. Corneal
allotransplantation was performed at day 0. The hMSC pre-
treatment was not effective in preventing allograft rejection in
mice in which macrophages were depleted at the time of hMSC
injection (Fig. 5E).
In a parallel experiment, we found that adoptive transfer of
B220+CD11b+ cells markedly suppressed the development of
EAU (Fig. 5 F–H). However, hMSC pretreatment did not sup-
press EAU development in mice depleted of monocytes/macro-
phages (Fig. 5I).
Together, results indicate that monocytes/macrophages are
required for the hMSC-mediated tolerance, and B220+CD11b+
monocytes/macrophages induced by hMSCs are capable of sup-
pressing corneal allograft rejection and EAU.
MSCs Prime Monocytes/Macrophages Within the Lung in Situ in a TSG-6–
Dependent Manner. A number of studies indicate that therapeutic
effects of MSCs are associated with the secretion of paracrine
factors. We therefore examined whether the factor(s) secreted by
MSCs might modulate the lung monocytes/macrophages toward a
Fig. 4. Impact of lung B220+CD11b+ vs. B220−CD11b+ cells on CD4+ cells
in vitro. (A) Giemsa staining of B220+CD11b+ vs. B220−CD11b+ cells isolated
from the lung tissue of mice at day 0 after i.v. injections of MSC at days −7 and
−3. (B) Flow cytometry results for CFSE dilution in CD4+ cells purified from blood
of naive mice upon coculture with B220+CD11b+ or B220−CD11b+ cells. (C) Flow
cytometric analysis for expression of IFN-γ and IL-17 on CD4+ cells under Th1 or
Th17 polarizing condition. Data depict the percentage of IFN-γ+CD4+ cells and
IL-17+CD4+ cells among CD4+ cells. Each dot indicates a single animal, and the
bar indicates the mean ± SD (*P < 0.05, **P < 0.01, and ***P < 0.001).
Fig. 5. Adoptive transfer of the lung B220+CD11b+ cells induced by MSC
ameliorates corneal allograft rejection and EAU. (A) Schema of B220+CD11b+
or B220−CD11b+ cell transfer in a corneal transplant model. (B) Survival
curve of corneal grafts. Allo, allogeneic grafts; Auto, syngeneic autografts.
(C) Quantitative flow cytometry results for IFN-γ+CD4+ cells in DLNs. (D) Real-
time RT-PCR assays of the cornea. (E) Effects of depletion of monocytes/
macrophages on graft survival. PBS-LIP, PBS solution-encapsulated liposome;
Cl2MDP-LIP, clodronate-encapsulated liposome. (F) Schema of B220
+CD11b+
or B220−CD11b+ cell transfer in an EAU model. (G) H&E staining of retinal
cross-sections (original magnification of 100×). Disease score assigned by
retinal histologic examination. (H) Real-time RT-PCR assays of the whole
eye. (I) Effects of depletion of monocytes/macrophages on EAU develop-
ment as assessed by histological disease score. Dot represents an individual
animal, and data are presented as mean ± SD from three independent
experiments, each experiment with three mice per group (*P < 0.05, **P <
0.01, and ***P < 0.001).





















regulatory phenotype. To this end, we used an in vitro transwell
system to coculture the lung cells of naive mice with hMSCs. As a
result, we found that the hMSC coculture significantly increased
the percentage of B220+ cells among lung CD11b+ cells (Fig. 6A).
The B220+CD11b+ cells expressed higher levels of IL-10 compared
with B220−CD11b+ cells (Fig. 6B). Next, to identify the paracrine
factor(s) of hMSCs associated with an increase in B220+CD11b+
cells, we performed microarrays to detect changes in the hMSC
transcriptome following incubation with the mouse lung cells. Of
interest were the gene(s) that encode secreted proteins and were
up-regulated by more than twofold in hMSCs upon coculture with
lung cells (Table S1). Of the 11 up-regulated genes for secreted
proteins, the following four genes have been previously shown to be
associated with immunomodulatory and antiinflammatory effects
of MSCs: stanniocalcin-1 (STC-1) (18), TSG-6 (4, 5, 11, 19), TGF-
β (7, 20, 21), and prostaglandin endoperoxidase synthase 2 (PTGS-
2) (10, 12, 21, 22). To examine whether any of these genes are
indeed increased in the lung of mice in vivo after i.v. hMSC in-
jection, we performed human-specific real-time RT-PCR assays to
analyze the lungs for expression of the four genes 12 h after i.v.
infusion of hMSCs in mice. Among the four genes, the most highly
up-regulated human transcript was TSG-6 (125-fold; Fig. S5). To
confirm whether TSG-6 expression of hMSCs is required for the
induction of B220+CD11b+ cells, we cocultured lung CD11b+ cells
with hMSCs transfected with TSG-6 siRNA- or control scrambled
(SCR) siRNA (siRNA). The TSG-6 siRNA-transfected hMSCs did
not increase the percentage of B220+CD11b+ cells, whereas SCR
siRNA-transfected hMSCs significantly enhanced B220+CD11b+
cells (Fig. 6C). Similarly, infusions of hMSCs with TSG-6 knock-
down into mice at days −7 and −3 did not induce MHC class
II+B220+CD11b+ cells in the lung (Fig. 6 D and E).
TSG-6 Expression of MSC Is Required for Tolerance in Vivo. To con-
firm that TSG-6 expression of hMSCs contributes to tolerance
induction by hMSCs, we injected TSG-6 siRNA- or SCR siRNA-
transfected hMSCs into naive mice at days −7 and −3 and in-
duced EAU at day 0 (Fig. 6F). The pretreatment with TSG-6
knockdown hMSCs was not effective in suppressing intraocular
inflammation and preventing retinal damage in mice with EAU,
whereas SCR siRNA-transfected hMSCs ameliorated EAU (Fig.
6 G and H).
Discussion
In this study, we tested the hypothesis that MSCs induce immune
tolerance by activating the endogenous immune regulatory sys-
tem of the recipient. To exclude the effects of direct immuno-
suppression by MSCs, we injected MSCs into mice at least 72 h
before immune challenge to the eye. As a result, we found that
the mice were protected from allo- and autoimmune attacks to
the eye even though MSCs no longer existed in the system. Be-
cause our findings are similar to an experimental strategy of
preexposing a tissue to stimuli to diminish the vulnerability of the
tissue to a subsequent attack (“preconditioning”) (23), we term
the induced protection observed with hMSCs as “MSC pre-
conditioning.” Similar protection has been observed in ischemia
or endotoxin tolerance, in which preexposure to ischemia or li-
popolysaccharide results in attenuated tissue injury during sub-
sequent insults (23–25). The nature of the induced protection
and underlying mechanisms of preconditioning are not yet clear,
but studies suggest that innate immune cells such as monocytes/
macrophages play a central role (26–28). Here we found that the
MSC preconditioning involved a distinct subset of suppressive
MHC II+B220+CD11b+ monocytes/macrophages in the lung.
Studies previously suggested that MSCs induce immune toler-
ance by up-regulating CD4+CD25+FoxP3+ Tregs (6, 7). An elegant
study by Akiyama et al. showed that i.v. infusion of mouse bone
marrow MSCs into naive mice induced T-cell apoptosis in periph-
eral blood and bone marrow from 6 to 72 h after infusion (6). The
apoptotic T cells triggered macrophages in the spleen to produce
TGF-β that subsequently resulted in the up-regulation of CD4+
CD25+FoxP3+ Tregs in peripheral blood at 24 and 72 h. Consistent
with this report, we observed an increase in CD4+CD25+FoxP3+
cells in peripheral blood that lasted until 96 h after MSC infusion.
However, a distinct type of suppressive MHC II+B220+CD11b+
monocytes/macrophages was induced at higher levels in the lung by
hMSCs and lasted longer in mice than CD4+CD25+FoxP3+ Tregs.
These monocytes/macrophages were effective in protecting against
EAU and corneal allograft rejection independently of FoxP3+
Tregs, indicating a direct role of monocytes/macrophages in the
MSC-induced tolerance.
Modulation of monocyte/macrophage function is a crucial com-
ponent of the host immune response. Recent studies showed that
monocytes/macrophages can reprogram their responses toward
immunogenic or tolerogenic phenotypes depending on the type and
concentration of ligands they encountered, in the phenomenon
termed “trained immunity and tolerance” (27, 28). In this context,
our study provides a possibility that MSCs use the plasticity of
monocytes/macrophages and prime them to produce tolerance. The
involvement of monocytes/macrophages in mediating therapeutic
effects of MSCs has been previously demonstrated (29). Nemeth
et al. showed that i.v. administration of mouse MSCs before or
shortly after sepsis induction reprogrammed the lung monocytes/
macrophages to increase IL-10 production and reduced mortality
in mice (10). The beneficial effects of mouse MSCs on macro-
phages were caused by the release of prostaglandin E2 (PGE2) by
MSCs. Another study by Choi et al. demonstrated that i.p. in-
jection of hMSCs modulated peritoneal macrophages to suppress
the production of proinflammatory cytokines and attenuated
zymosan-induced peritonitis in mice (11). The effects of hMSCs
on macrophages were mediated by TSG-6 secreted by hMSCs.
Fig. 6. MSCs with TSG-6 knockdown neither induceMHC class II+B220+CD11b+
cells nor prevent EAU. (A) Flow cytometry results for B220 expression in
mouse lung CD11b+ cells that were cocultured with MSCs. (B) Represen-
tative flow cytometry plot of IL-10 intracellular staining in B220+CD11b+
cells vs. B220−CD11b+ cells. (C) The percentage of B220+CD11b+ cells in mouse
lung CD11b+ cells that were cocultured with TSG-6 siRNA- or SCR-transfected
MSCs. (D) Schema of experiments. (E ) Flow cytometry results for MHC class
II+B220+CD11b+ cells in the lung. Each dot indicates a single animal, and the bar
represents the mean ± SD. (F) Schema of TSG-6 siRNA MSC pretreatment in an
EAU model. (G) Histologic disease score. (H) Real-time RT-PCR assays of the eye.
Data are presented as mean ± SD from two independent experiments, each with
three mice per group (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).
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Similarly, we found that the exposure of hMSCs to lung mono-
cytes/macrophages activated hMSCs to produce TSG-6, which led
to reprogramming of monocyte/macrophage toward a tolerogenic
phenotype that is potent in preventing auto- and alloimmune
responses. However, unlike the study by Nemeth et al., we did not
observe any change in the expression of PTGS2 in hMSCs in vivo,
suggesting that TSG-6, not PGE2, might be a main factor medi-
ating the MSC action in our models.
TSG-6 is a 30-kDa glycoprotein expressed by many cells in re-
sponse to proinflammatory cytokines, and has multiple actions
related to modulation of inflammation and stabilization of the
extracellular matrix (30, 31). Recently, observations by our group
and others identified TSG-6 as being responsible for the ben-
eficial effects of MSCs in the treatment of disease models of the
heart (4), cornea (5, 19, 32), brain (33), lung (34), and pancreas
(35). TSG-6 exerts its antiinflammatory actions through multiple
mechanisms, one of which is the modulation of myeloid cells into a
tolerogenic phenotype. In the study by Lee et al., TSG-6 treatment
of bone marrow-derived myeloid precursors increased the number
of CD11c+B220+CD8α+ cells of plasmacytoid dendritic sub-
type, and transfer of myeloid cells cultured with TSG-6 delayed
the development of autoimmune diabetes in nonobese diabetic
mice (35). Therefore, MSCs and their secreted protein TSG-6 may
modulate the endogenous immune system through actions on
myeloid cells. Further research would be needed to investi-
gate the detailed mechanism by which MSCs and TSG-6
reprogram monocytes/macrophages.
In conclusion, our study provides a mechanistic insight into
how an exogenous infusion of MSCs modulates immune re-
sponses despite transient engraftment. The MSCs precondition
the recipient immune system toward a state of tolerance through
induction of nonspecific innate tolerance involving a distinct
subset of suppressive lung monocytes/macrophages.
Materials and Methods
Detailed information on study materials and methods is provided in SI Ma-
terials and Methods. The experimental protocols were approved by the in-
stitutional animal care and use committee of Seoul National University
Hospital Biomedical Research Institute (nos. 12–0247-C1A0 and 13–0104-
C3A0). EAU was induced as we previously reported (36). Corneal trans-
plantation was performed as we previously described (5).
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